Cargando…
Targeted IgMs agonize ocular targets with extended vitreal exposure
Treatment of ocular disease is hindered by the presence of the blood-retinal barrier, which restricts access of systemic drugs to the eye. Intravitreal injections bypass this barrier, delivering high concentrations of drug to the targeted tissue. However, the recommended dosing interval for approved...
Autores principales: | Chen, Yvonne, Paluch, Maciej, Zorn, Julie A., Rajan, Sharmila, Leonard, Brandon, Estevez, Alberto, Brady, John, Chiu, Henry, Phung, Wilson, Famili, Amin, Yan, Minhong, Ciferri, Claudio, Matsumoto, Marissa L., Lazar, Greg A., Crowell, Susan, Hass, Phil, Agard, Nicholas J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577241/ https://www.ncbi.nlm.nih.gov/pubmed/32936727 http://dx.doi.org/10.1080/19420862.2020.1818436 |
Ejemplares similares
-
Harnessing MerTK agonism for targeted therapeutics
por: Kedage, Vivekananda, et al.
Publicado: (2019) -
Age-Related Loss of Human Vitreal Viscoelasticity
por: Schulz, André, et al.
Publicado: (2019) -
Some Physicochemical Remarks on Spontaneous Emulsification of Vitreal Tamponades
por: Costagliola, Ciro, et al.
Publicado: (2014) -
Traumatic chorioretinal folds treated with intra-vitreal triamcinolone injection
por: Kim, Kook Young, et al.
Publicado: (2013) -
Intra-vitreal injection of methotrexate in experimental endotoxin-induced uveitis in rabbit
por: Abbaszadeh Hasiri, Mohammad, et al.
Publicado: (2018)